Impact of Seizures and Status Epilepticus on Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage

Seizures and nonconvulsive status epilepticus (NCSE) are a common complication in patients with aneurysmal subarachnoid hemorrhage (aSAH). They are commonly divided into onset (occurring within 24 h after hemorrhage), acute (occurring within the first 7 days after hemorrhage, also termed “provoked seizures/NCSE”), and remote symptomatic (occurring after the initial acute stage of disease, leading to the diagnosis of epilepsy) [1, 2]. Although onset seizures occur in around 4–19% [3‐5] of patients with aSAH, early seizures occur in around 1–11.7% [6‐9]. Both onset and early seizures were early on implied to predict unfavorable outcome because of their correlation to rebleeding [3, 10] before early surgical therapy was routinely available. This result could not consistently be replicated in later studies [3, 5, 9, 11, 12]. Recently, however, seizure burden (as a quantification of the duration of subclinical seizures) has been found to impair cognitive outcome after 3 months, implying that possibly only higher functions are impaired by recurrent seizures [8]. Late seizures (and thus diagnosis of epilepsy) occur in around 1–30% of patients [9, 13, 14] (depending on the length of follow-up). NCSE occurs in 3–15% [15, 16] of patients with aSAH. Unlike self-limiting seizures, its presence has generally been found to be detrimental, with unfavorable outcome in up to 92% of patients [17, 18]. According to the suggested definition of the International League Against Epilepsy (ILAE), seizures and NCSE have a period of 7 days during which their occurrence is deemed provoked in a multitude of diseases (e.g., stroke, traumatic brain injury, infectious/autoimmune central nervous system disease, etc.) [1]. In aSAH, this definition is hampered by the occurrence of delayed cerebral ischemia (DCI) up to 14 days after ictus. Thus, studies have commonly averted from reporting acute symptomatic and remote symptomatic seizures but differentiated early (ranging from inclusion of onset seizures, up to 24–48 h after ictus, up to 1 or 2 weeks after ictus, or even up to hospital discharge) and late seizures (7–14 days after ictus or after discharge) [6, 19]. This variability in definition might considerably impair and alter outcome prediction. Furthermore, studies commonly combine self-limiting seizures and NCSE within the reports. The primary aim of this study was to provide an in-depth description of seizures and NCSE in a current cohort of patients with aSAH by rigorous retrospective analysis with respect to their timing and type. A secondary aim was to provide a quantification of their predictive value for outcome prediction in aSAH.

The study was approved by the local ethics committee (Cantonal Ethics Commission Zurich, Kantonale Ethikkomission 2019-00713) and was in accordance with the ethical standards laid down in the 2013 Declaration of Helsinki for research involving human participants. Informed consent was received before inclusion by the patient or their legal medical representative.

The patients were selected from a prospective database of consecutive patients who were admitted between 2016 and 2020 to the neurocritical care unit of the University Hospital Zurich because of an aSAH. Only patients with imaging evidence of a ruptured intracranial aneurysm were included. Patients with immediate withdrawal of life-sustaining therapy because of the severity of the disease and patients with a preexisting diagnosis of epilepsy at onset were excluded. Data collection was performed by scanning the electronic health records for demographic characteristics, clinical and radiological information (Fisher grade, location of ruptured aneurysm, presence of other unruptured aneurysms, presence of intracerebral as well as intraventricular or subdural hemorrhage including their location, and presence of hydrocephalus), treatment modality (clipping, coiling or flow diverter–based therapy), clinical course (occurrence of ventriculostomy-related infection, vasospasm, or DCI), and outcome data. The radiological findings aside from DCI and vasospasm were extracted from the first computed tomography (CT) (including CT angiography) imaging. DCI was defined as a cerebral infarction on CT scans or magnetic resonance images, excluding infarction caused by other causes (such as endovascular treatment or clipping) and infarction already present within the CT scan 24–48 h after aneurysm securing [20]. The clinical correlate of DCI (occurrence of focal neurological impairment or Glasgow Coma Scale [GCS] decrease of 2 or more points for at least 1 h) was also excluded to reduce the bias caused by the retrospective design of this study. Transcranial Doppler ultrasound monitoring was performed daily. The cerebral flow velocities were not used for the diagnosis of vasospasm but only triggered the performance of a CT scan, including angiography (in case of increasing or increased flow velocities). The diagnosis of vasospasm was reserved for cases with respective description on CT, magnetic resonance, or digital subtraction angiography. All patients received nimodipine as a vasospasm prophylaxis. The dosage was either 60 mg per 4 h orally or 2 mg per hour intravenously in cases with relevant hemodynamic instability (i.e., to be able to quickly reduce the dosage). The Charlson Comorbidity Index was assessed to evaluate relevant comorbidity. The Charlson Comorbidity Index correlates with mortality and consists of differently weighted medical conditions [21]. Outcome is presented by using the Glasgow Outcome Scale Extended (GOSE) extracted from routine follow-up consultations at 3 months (which include a neurological examination and a description of current occupation, including the percentage of working capability).

Seizures (that are regularly assessed and noted during the hospital stay and during each follow-up consultation at 3 months and at 12 months), including their type and timing, were extracted from the medical reports. Acute symptomatic seizures/NCSE were defined to have occurred within 7 days after hemorrhage. Remote symptomatic seizures/NCSE were defined to have occurred 8 days or later after hemorrhage (in the absence of other seizure provoking factors). Provoked seizures due to complication were defined as seizures that occurred because of clear seizure provoking factors (e.g., severe metabolic or electrolyte disturbance, acute progressive hydrocephalus, rebleed, etc.). Electroencephalogram (EEG) reports were extracted and verified by two experienced neurologists (LI and SB) through reevaluation of the EEGs. NCSE was diagnosed by using the Salzburg criteria [22]. Epilepsy was diagnosed by the occurrence of remote symptomatic seizures/NCSE 8 days or later after initial hemorrhage. Furthermore we provide the number of patients who had their first remote symptomatic seizure/NCSE between 8 and 14 days after hemorrhage (the vasospasm phase). At the neurocritical care unit of the University Hospital Zurich, EEGs are performed on the basis of the judgment of the treating physician alone. EEGs last for at least 20 min. Anesthetics are stopped before the start of EEG acquisition (i.e., midazolam is stopped at least 6 h before acquisition, propofol at least 20 min before acquisition, no inhalative anesthetics are used). In case signs of sedation were found during EEG inspection, the EEG is repeated later on. Continuous EEG monitoring is only used in cases with refractory NCSE or need for deep sedation because of increased intracerebral pressure. Prophylactic antiseizure medication (ASM) is not routinely administered at our institution. In case of seizures (either with clinical correlate or subclinical seizure found during EEG monitoring) or diagnosis of NCSE, ASM was started or increased (in case of recurrent seizures or persistent NCSE). Epileptiform discharges alone did not lead to an escalation of ASM.

This study provides a detailed description of the association of seizures/NCSE (divided into onset, acute symptomatic, and remote symptomatic) and outcome in a current cohort of patients with aSAH.

Early studies found seizures at onset to be associated with unfavorable outcome [3, 10]. Later studies as well as our current study could not replicate this result probably due to reduced rates of rebleeding [3, 5, 9, 11, 12]. Furthermore, acute self-limiting seizures were not significantly associated with unfavorable outcome in our patient group. Conversely, acute symptomatic NCSE was associated with unfavorable outcome even after correction for the known risk factors (including Hunt-Hess grade, Fisher grade, and DCI). Acute symptomatic NCSE occurred in 1 versus 18 patients with favorable/unfavorable outcome, respectively, leading to a high positive predictive value for unfavorable outcome. Conversely, because of the low number of patients affected by NCSE (8%) negative predictive value remained low (altogether leading to a relatively large CI of NCSE OR in the multivariate models). These results imply that NCSE independently impaired achievement of favorable outcome in patients who may otherwise have had a reasonable prognosis. This assumption was further supported by the subgroup analysis. All seizures including NCSE were expectedly closely associated with larger amounts of blood within the initial CT scan (i.e., higher Fisher grade) [23, 24]. However, and possibly most surprisingly, both acute symptomatic NCSE as well as single self-limiting seizures were associated with unfavorable outcome exclusively in patients with a low Hunt-Hess grade, whereas these lost their predictive value in patients with a high Hunt-Hess grade.

Single self-limiting seizures and NCSE lead to a reduction of GCS: although single self-limiting seizures only lead to a transient reduction of GCS, NCSE leads to a continuous reduction of GCS either due to the seizing itself, or also due to its therapy (intravenous application of benzodiazepines, anesthetics, etc.). This renders the close evaluation of clinical signs of DCI impossible, and thus possibly the preventable secondary infarction due to DCI might be missed. This thesis might also explain why single seizures/NCSE primarily affected outcome in patients with low Hunt-Hess. These are the only patients who can be closely monitored for clinical signs of DCI, whereas patients with high Hunt-Hess grades commonly retain a low GCS independently of occurrence of single seizures or NCSE. However, whether NCSE poses a direct risk factor for unfavorable outcome, just impairs early diagnosis of DCI, or if they are just an expression of the severity of the disease itself cannot be determined in our study.

Between 2016 and 2020 there was an increase of EEGs performed as well as an increase of NCSE diagnosed emphasizing the importance of bearing-in-mind and evaluating presence of NCSE in case of unclear clinical deterioration to allow for earliest treatment possible. The vast majority of NCSE (irrespective of acute/remote origin) was first diagnosed between day 1 and 7 after aSAH in patients with unfavorable outcome (Fig. 2). The first patient (with unfavorable outcome) with his first NCSE at a later time-point was diagnosed at day 18 after aSAH. Diagnosis of epilepsy was found in similar rates as in previous studies [9, 13, 14]. Surprisingly, although only 16.3% of patients could be diagnosed with epilepsy, 25.5% of patients were still prescribed an ASM one year after onset of aSAH. Although prophylactic ASM has not conclusively been found to be associated with unfavorable outcome, there is evidence that phenytoin might impair outcome after aSAH [4, 11, 25]. Thus, clear documentation of the indication for the initiation of ASM as well as early/planned tapering of medication after the acute phase remain essential.

This study has several limitations. Because of the retrospective design, there was no standardized performance of EEGs. Whether an EEG was performed at all to allow for the diagnosis of NCSE was decided by the treating physician. Routine EEGs lasted 20 min. Longer EEGs or even continuous EEG monitoring would surely have increased the number of seizures/NCSE diagnosed. Particularly in poor grade aSAH, continuous EEG has shown to be beneficial their detection with up to 18% being diagnosed with nonconvulsive seizures and up to 13% being diagnosed with NCSE after a median monitoring duration of 3–4 days [17, 26, 27]. Other predictors of unfavorable outcome that can be extracted from continuous EEG and were unavailable in our study (i.e., absence of sleep architecture, total burden/duration of seizures/NCSE) [8, 17] might have improved the outcome prediction, but could also have led to earlier withdrawal of life-sustaining therapy. Some patients might have been treated with ASM even if a seizure was only suspected (i.e., due to an unclear motor event). This might have reduced the number of seizures/NCSE documented. However, in aSAH, NCSE has been found to be highly refractory to treatment, and the effect of ASM on the incidence of seizures in the early phase of aSAH remains controversial [4, 11, 19, 28, 29]. Furthermore, ASM might have even impaired outcome itself, as some ASM (especially phenytoin) have been shown to possibly pose a negative impact on outcome after aSAH [4, 11, 25]. On a long-term basis, as many patients were treated even after discharge, incidence of epilepsy is most probably underestimated.

Currently, there is no unified definition for the time limit of acute symptomatic seizures in aSAH. ILAE recommends acute symptomatic seizures to be defined as events occurring in close temporal relationship with an acute insult to the central nervous system [1]. Most commonly the time limit is set at 7 days after ictus. DCI occurs in around 30% of patients with aSAH [30, 31]. Particular in those cases in which DCI leads to infarction, the acute symptomatic time period most likely should be extended or even “restarted” to perfectly accommodate the recommendations proposed by the ILAE. However, although this might lower the false negative rate, it would unquestionably also increase the false positive rate of acute symptomatic seizure diagnosis. Lastly, unless a seizure or NCSE starts during an EEG its exact cortical origin cannot be determined in the absence of clearly lateralizing or localizing seizure manifestations, thus rendering the differentiation between acute symptomatic (i.e., due to DCI) and remote symptomatic seizure (i.e., due to the initial hemorrhage) vastly more difficult. In our cohort, the vast majority of NCSE occurred within the first 7 days; even more important, the vast majority of NCSE within the first 7 days occurred within the first 3 days after hemorrhage, thus before the start of the vasospasm phase (Fig. 2). These observations make a clear association of NCSE to DCI in comparison with the initial hemorrhage itself less likely. Altogether, in our cohort, the inclusion of later NCSE would most likely not have changed the results. Yet, we still believe that using a 7-day cut-off (although being somewhat arbitrary) will allow for better comparability with other studies and minimize the false positive rate.

Seizures and NCSE remain a common occurrence in aSAH. Acute symptomatic NCSE in particular is independently associated with an unfavorable outcome. We propose that the ictal or postictal reduction of GCS might render close clinical evaluation for clinical signs of DCI impossible, and thus possibly leading to a delayed diagnosis of DCI and possibly preventable secondary infarction due to DCI. This thesis is supported by the subgroup analysis showing that seizures and NCSE primarily affected outcome in patients with a low Hunt-Hess grade while leaving patients with a high Hunt-Hess grade unaffected. Prospective studies with predefined protocols regarding the timing of EEG and CT imaging must be performed to validate this theory. Lastly, the performance of EEGs remains essential for outcome prediction in aSAH and treatment thereof, as NCSE incidence increased throughout the years with the increase of patients receiving an EEG.